← Leaderboards
Noemi Andor
H. Lee Moffitt Cancer Ctr & Res Inst
$3,764,187
Attributed
$3,853,926
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $850.6K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,853,926 · 5
By mechanism
R37$2,095,115 · 1
R00$746,851 · 1
R21$499,193 · 1
K99$333,288 · 1
R03$179,479 · 1
Top collaborators
- Laura Madeline Heiser2 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Florian Karreth$4,692,414
- Laura Madeline Heiser$5,676,081
- Ariosto S Siqueira Silva$1,904,085
- Mehdi Damaghi$4,059,891
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsCellsTumorPhenotypeFitnessTranscriptomeResponseSingle-Cell Rna SequencingEvolutionGenomeCancer CellMalignant Stomach NeoplasmDna DamageTumor HeterogeneityCancer Cell LineGeneticCell LineSingle Cell SequencingGrowthBiological MarkersApoptosisGenerationsImageEnvironment
Grant awards (14)
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy$562,055
R37 · FY2025 · CA · contact PI
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy$480,392
R37 · FY2024 · CA · contact PI
Engineering model-based systems to monitor and steer subclonal dynamics$187,087
R21 · FY2024 · CA · contact PI
IMAT-ITCR Collaboration: Engineering model-based systems to monitor and steer subclonal dynamics$75,785
R21 · FY2024 · CA · contact PI
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy$532,569
R37 · FY2023 · CA · contact PI
Engineering model-based systems to monitor and steer subclonal dynamics$236,321
R21 · FY2023 · CA · contact PI
A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments$81,686
R03 · FY2023 · CA · contact PI
Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy$520,099
R37 · FY2022 · CA · contact PI
A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments$97,793
R03 · FY2022 · CA · contact PI
A clone's genomic stability as biomarker of its DNA-damage resilience$248,992
R00 · FY2021 · CA · contact PI
A clone's genomic stability as biomarker of its DNA-damage resilience$248,930
R00 · FY2020 · CA · contact PI
A clone's genomic stability as biomarker of its DNA-damage resilience$248,929
R00 · FY2019 · CA · contact PI
A clone's genomic stability as biomarker of its DNA-damage resilience$166,644
K99 · FY2018 · CA · contact PI
A clone's genomic stability as biomarker of its DNA-damage resilience$166,644
K99 · FY2017 · CA · contact PI